

## MT2019-06: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

**Status:** Recruiting

[Eligibility Criteria](#)

[Conditions & Interventions](#)

### More Information

**Description:** Evaluate the efficacy of treatment with bb1111 (also known as LentiGlobin BB305 Drug Product for Sickle Cell Disease) in subjects with sickle cell disease (SCD).

**Contact(s):** Danielle Jin - zhuxx003@umn.edu

**Principal Investigator:** Ashish Gupta

**IRB**

**Number:** STUDY00006923

**System ID:** 25197

---

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.